SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2025

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

14.

SUBSEQUENT EVENTS

FDA Approval

In April 2025, the FDA approved the Company’s Prior Approval Supplement (the “PAS”) for its innovative yield enhancement production process benefiting both ASCENIV and BIVIGAM.

Share Repurchase Program 

In May 2025, the Company's Board of Directors authorized a share repurchase program of up to $500.0 million of the Company’s outstanding shares of common stock. Repurchases under the program may be made from time to time through open market purchases or through privately negotiated transactions subject to market conditions, applicable legal requirements, and other relevant factors. Open market repurchases will be structured to occur in accordance with the requirements of Rule 10b-18. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of shares under this authorization. The timing and number of shares repurchased under the program will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The program does not obligate the Company to acquire any particular amount of its common stock, and may be modified, suspended, or terminated at any time at the Company’s discretion. The program has no expiration date.

Debt Reorganization

On May 5, 2025, the Company borrowed $30.0 million under its revolving credit facility with Ares, which the Company used to repay an additional $30.0 million against the Company’s term loan facility with Ares on May 6, 2025. Following such transactions, the Company had $72.5 million outstanding under its revolving credit facility and $2.5 million outstanding under its term loan facility. It is anticipated that the Company’s cost of current outstanding debt will be reduced from these transactions.